April 22nd 2025
The commitment will include new, state-of-the-art R&D facilities as well as new or expanded manufacturing sites in multiple states.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Sartorius Supports ABL Europe in Viral Vector GMP Capacity Expansion
March 19th 2018Sartorius has delivered to ABL’s Strasbourg facility, a GMP viral vector manufacturing package solution that includes single-use bioreactors and an automation platform for normal flow filtration, tangential filtration, and mixing.
Annex 1 Misses the Mark–Expanded Version
March 14th 2018A previously published article presented difficulties with the revised European guidelines on sterile manufacturing. The authors included a brief summary of the comments developed on the draft document. This article expands upon that summary, outlines the authors' rationale, and highlights the most difficult aspects of the revision draft.